famotidine has been researched along with Melanoma in 11 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Outpatient intravenous IL-2 and famotidine has activity in melanoma." | 7.78 | Outpatient intravenous interleukin-2 with famotidine has activity in metastatic melanoma. ( Johnson, E; Perez, M; Quan, FM; Quan, WD, 2012) |
| " It has been previously shown that the patients with metastatic melanoma or kidney cancer may be treated safely with pulse IL-2 daily for 5 days preceded by intravenous famotidine." | 7.77 | Pulse interleukin-2 with famotidine induces CD56+ lymphocytes in the peripheral blood of patients with metastatic melanoma or kidney cancer. ( Gagnon, GA; Quan, FM; Quan, WD; Walker, PR, 2011) |
| "Famotidine may increase LAK cytotoxicity against neoplastic cells by allowing for greater IL-2 uptake at the IL-2 receptor on lymphocytes." | 6.74 | Activity of continuous infusion + pulse interleukin-2 with famotidine in metastatic melanoma. ( Quan, FM; Quan, WD, 2009) |
| "Famotidine may enhance the activity of T-cells further by allowing for increased IL-2 internalization by the IL-2 receptor on lymphocytes." | 5.36 | Pulse infusion interleukin-2 with famotidine and cyclophosphamide has activity in previously treated metastatic melanoma. ( Knupp, C; Quan, F; Quan, W; Walker, P, 2010) |
| "Famotidine may increase LAK activity by increasing IL-2 internalization by the IL-2 receptor on lymphocytes." | 5.35 | High-dose intensity pulse interleukin-2 with famotidine has activity in metastatic melanoma. ( King, LA; Liles, DK; Picton, M; Quan, FM; Quan, WD; Tyre, C; Walker, PR, 2008) |
| "Famotidine may increase IL-2 internalization by the IL-2 receptor on T-lymphocytes." | 5.35 | Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer. ( King, LA; Quan, FM; Quan, WD; Walker, PR, 2008) |
| "Two (2) patients with kidney cancer have been converted to complete responders with resection of residual disease, remaining without relapse at 5+ and 20+ months." | 5.33 | Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2. ( Elsamaloty, HM; Ghai, V; Liles, DK; Quan, FM; Quan, WD; Ramirez, M; Vinogradov, M; Walker, PR, 2006) |
| "Famotidine may enhance the lysis of tumors by cytotoxic lymphocytes." | 5.32 | High-dose continuous infusion plus pulse interleukin-2 and famotidine in melanoma. ( Jackson, S; Khan, N; Quan, W; Ramirez, M; Taylor, WC; Vinogradov, M, 2004) |
| "High-dose, continuous-infusion interleukin-2 (IL-2) followed by pulse dose and concurrent administration of famotidine has demonstrated response rates of 64% and 33% in patients with metastatic melanoma and metastatic renal cell carcinoma, respectively." | 4.84 | Nursing care of patients receiving high-dose, continuous-infusion interleukin-2 with pulse dose and famotidine. ( Quan, W; Tyre, CC, 2007) |
| " Outpatient intravenous IL-2 and famotidine has activity in melanoma." | 3.78 | Outpatient intravenous interleukin-2 with famotidine has activity in metastatic melanoma. ( Johnson, E; Perez, M; Quan, FM; Quan, WD, 2012) |
| " It has been previously shown that the patients with metastatic melanoma or kidney cancer may be treated safely with pulse IL-2 daily for 5 days preceded by intravenous famotidine." | 3.77 | Pulse interleukin-2 with famotidine induces CD56+ lymphocytes in the peripheral blood of patients with metastatic melanoma or kidney cancer. ( Gagnon, GA; Quan, FM; Quan, WD; Walker, PR, 2011) |
| "Famotidine may increase LAK cytotoxicity against neoplastic cells by allowing for greater IL-2 uptake at the IL-2 receptor on lymphocytes." | 2.74 | Activity of continuous infusion + pulse interleukin-2 with famotidine in metastatic melanoma. ( Quan, FM; Quan, WD, 2009) |
| "Famotidine may enhance the activity of T-cells further by allowing for increased IL-2 internalization by the IL-2 receptor on lymphocytes." | 1.36 | Pulse infusion interleukin-2 with famotidine and cyclophosphamide has activity in previously treated metastatic melanoma. ( Knupp, C; Quan, F; Quan, W; Walker, P, 2010) |
| "Famotidine may increase LAK activity by increasing IL-2 internalization by the IL-2 receptor on lymphocytes." | 1.35 | High-dose intensity pulse interleukin-2 with famotidine has activity in metastatic melanoma. ( King, LA; Liles, DK; Picton, M; Quan, FM; Quan, WD; Tyre, C; Walker, PR, 2008) |
| "Famotidine may increase IL-2 internalization by the IL-2 receptor on T-lymphocytes." | 1.35 | Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer. ( King, LA; Quan, FM; Quan, WD; Walker, PR, 2008) |
| "Two (2) patients with kidney cancer have been converted to complete responders with resection of residual disease, remaining without relapse at 5+ and 20+ months." | 1.33 | Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2. ( Elsamaloty, HM; Ghai, V; Liles, DK; Quan, FM; Quan, WD; Ramirez, M; Vinogradov, M; Walker, PR, 2006) |
| "Famotidine may enhance the lysis of tumors by cytotoxic lymphocytes." | 1.32 | High-dose continuous infusion plus pulse interleukin-2 and famotidine in melanoma. ( Jackson, S; Khan, N; Quan, W; Ramirez, M; Taylor, WC; Vinogradov, M, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (72.73) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Quan, WD | 7 |
| Walker, PR | 5 |
| Picton, M | 1 |
| Quan, FM | 7 |
| King, LA | 2 |
| Tyre, C | 1 |
| Liles, DK | 3 |
| Quan, W | 4 |
| Knupp, C | 1 |
| Quan, F | 2 |
| Walker, P | 2 |
| Gagnon, GA | 1 |
| Perez, M | 1 |
| Johnson, E | 1 |
| Ramirez, M | 3 |
| Taylor, WC | 1 |
| Vinogradov, M | 3 |
| Khan, N | 2 |
| Jackson, S | 1 |
| Taylor, C | 1 |
| Elsamaloty, HM | 1 |
| Ghai, V | 1 |
| Milligan, KS | 1 |
| Cuenca, RE | 1 |
| Tyre, CC | 1 |
1 review available for famotidine and Melanoma
| Article | Year |
|---|---|
Nursing care of patients receiving high-dose, continuous-infusion interleukin-2 with pulse dose and famotidine.
Topics: Anti-Ulcer Agents; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Drug | 2007 |
3 trials available for famotidine and Melanoma
| Article | Year |
|---|---|
Activity of continuous infusion + pulse interleukin-2 with famotidine in metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Famotidine; Fema | 2009 |
Administration of high-dose continuous infusion interleukin-2 to patients age 70 or over.
Topics: Adenosine; Aged; Aged, 80 and over; Aging; Capillary Leak Syndrome; Famotidine; Hemodynamics; Humans | 2005 |
Continuous infusion interleukin-2 and intravenous famotidine in metastatic melanoma.
Topics: Adult; Aged; Drug Therapy, Combination; Famotidine; Female; Humans; Infusions, Intravenous; Interleu | 2006 |
7 other studies available for famotidine and Melanoma
| Article | Year |
|---|---|
High-dose intensity pulse interleukin-2 with famotidine has activity in metastatic melanoma.
Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Disease Progression; Famotidine; Female; Humans; | 2008 |
Pulse infusion interleukin-2 with famotidine and cyclophosphamide has activity in previously treated metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cycl | 2010 |
Pulse interleukin-2 with famotidine induces CD56+ lymphocytes in the peripheral blood of patients with metastatic melanoma or kidney cancer.
Topics: CD56 Antigen; Famotidine; Humans; Infusions, Intravenous; Interleukin-2; Kidney Neoplasms; Killer Ce | 2011 |
Outpatient intravenous interleukin-2 with famotidine has activity in metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Famotidine; Female; | 2012 |
High-dose continuous infusion plus pulse interleukin-2 and famotidine in melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Drug Therapy, Combination; Famotidine; Female; H | 2004 |
Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2.
Topics: Aged; Drug Administration Schedule; Drug Synergism; Famotidine; Female; Humans; Immunotherapy; Infus | 2006 |
Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Cycloph | 2008 |